Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

829 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes.
Simmonds P, Bukh J, Combet C, Deléage G, Enomoto N, Feinstone S, Halfon P, Inchauspé G, Kuiken C, Maertens G, Mizokami M, Murphy DG, Okamoto H, Pawlotsky JM, Penin F, Sablon E, Shin-I T, Stuyver LJ, Thiel HJ, Viazov S, Weiner AJ, Widell A. Simmonds P, et al. Among authors: enomoto n. Hepatology. 2005 Oct;42(4):962-73. doi: 10.1002/hep.20819. Hepatology. 2005. PMID: 16149085 Review.
Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors.
Kurosaki M, Tanaka Y, Nishida N, Sakamoto N, Enomoto N, Honda M, Sugiyama M, Matsuura K, Sugauchi F, Asahina Y, Nakagawa M, Watanabe M, Sakamoto M, Maekawa S, Sakai A, Kaneko S, Ito K, Masaki N, Tokunaga K, Izumi N, Mizokami M. Kurosaki M, et al. Among authors: enomoto n. J Hepatol. 2011 Mar;54(3):439-48. doi: 10.1016/j.jhep.2010.07.037. Epub 2010 Sep 19. J Hepatol. 2011. PMID: 21129805
Comprehensive analysis for viral elements and interleukin-28B polymorphisms in response to pegylated interferon plus ribavirin therapy in hepatitis C virus 1B infection.
Maekawa S, Sakamoto M, Miura M, Kadokura M, Sueki R, Komase K, Shindo H, Komatsu N, Shindo K, Kanayama A, Ohmori T, Amemiya F, Takano S, Yamaguchi T, Nakayama Y, Kitamura T, Inoue T, Okada S, Enomoto N. Maekawa S, et al. Among authors: enomoto n. Hepatology. 2012 Nov;56(5):1611-21. doi: 10.1002/hep.25826. Hepatology. 2012. PMID: 22577043
Pretreatment prediction of the outcome of response-guided peginterferon-α and ribavirin therapy for chronic hepatitis C.
Masaki N, Sugiyama M, Shimada N, Tanaka Y, Nakamuta M, Izumi N, Watanabe S, Tsubota A, Komatsu M, Masaki T, Enomoto N, Yoneda M, Murata K, Ito K, Koike K, Mizokami M. Masaki N, et al. Among authors: enomoto n. J Gastroenterol Hepatol. 2014 Dec;29(12):1996-2005. doi: 10.1111/jgh.12646. J Gastroenterol Hepatol. 2014. PMID: 24910341 Free PMC article.
T cell recognition of hypervariable region-1 from hepatitis C virus envelope protein with multiple class II MHC molecules in mice and humans: preferential help for induction of antibodies to the hypervariable region.
Shirai M, Arichi T, Chen M, Masaki T, Nishioka M, Ikeda K, Takahashi H, Enomoto N, Saito T, Major ME, Nakazawa T, Akatsuka T, Feinstone SM, Berzofsky JA. Shirai M, et al. Among authors: enomoto n. J Immunol. 1999 Jan 1;162(1):568-76. J Immunol. 1999. PMID: 9886434
829 results